# Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors

> **NCT03891784** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University of Washington** · enrollment: 20 (actual)

## Conditions studied

- Advanced Digestive System Neuroendocrine Neoplasm
- Digestive System Neuroendocrine Tumor
- Foregut Neuroendocrine Tumor
- Hindgut Neuroendocrine Tumor
- Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm
- Metastatic Digestive System Neuroendocrine Neoplasm
- Midgut Neuroendocrine Tumor
- Pancreatic Neuroendocrine Tumor
- Refractory Digestive System Neuroendocrine Neoplasm

## Interventions

- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT03891784
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-31
- **Primary completion:** 2025-11-01
- **Final completion:** 2026-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03891784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03891784, "Abemaciclib in Treating Patients With Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03891784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*